about
Options for field diagnosis of human african trypanosomiasisEvaluation of the micro-CATT, CATT/Trypanosoma brucei gambiense, and LATEX/T b gambiense methods for serodiagnosis and surveillance of human African trypanosomiasis in West and Central AfricaEquivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sicknessBioluminescent imaging of Trypanosoma brucei shows preferential testis dissemination which may hamper drug efficacy in sleeping sicknessIsolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory miceAquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprolA panel of Trypanosoma brucei strains tagged with blue and red-shifted luciferases for bioluminescent imaging in murine infection modelsMelarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the CongoNew Trypanosoma evansi Type B Isolates from Ethiopian Dromedary CamelsExpression of Trypanosoma brucei gambiense Antigens in Leishmania tarentolae. Potential for Use in Rapid Serodiagnostic Tests (RDTs)Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration.Killing of Trypanozoon Parasites by the Equine Cathelicidin eCATH1.Expression of RoTat 1.2 cross-reactive variable antigen type in Trypanosoma evansi and T. equiperdum.Improved Models of Mini Anion Exchange Centrifugation Technique (mAECT) and Modified Single Centrifugation (MSC) for sleeping sickness diagnosis and staging.Flow cytometry-based methods for assessing soluble scFv activities and detecting antigens in solution.T. cruzi OligoC-TesT: a simplified and standardized polymerase chain reaction format for diagnosis of Chagas diseaseA CATT negative result after treatment for human African trypanosomiasis is no indication for cure.Human African trypanosomiasis control: Achievements and challenges.Phase II evaluation of sensitivity and specificity of PCR and NASBA followed by oligochromatography for diagnosis of human African trypanosomiasis in clinical samples from D.R. Congo and Uganda.Diagnostic accuracy of the Leishmania OligoC-TesT and NASBA-Oligochromatography for diagnosis of leishmaniasis in Sudan.Performance of parasitological and molecular techniques for the diagnosis and surveillance of gambiense sleeping sicknessCost-effectiveness of algorithms for confirmation test of human African trypanosomiasis.Revisiting the immune trypanolysis test to optimise epidemiological surveillance and control of sleeping sickness in West Africa.International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients.True versus apparent malaria infection prevalence: the contribution of a Bayesian approachDiagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study.Identification of stage biomarkers for human African trypanosomiasis.Recombinant antigens expressed in Pichia pastoris for the diagnosis of sleeping sickness caused by Trypanosoma brucei gambiense.Identification of peptide mimotopes of Trypanosoma brucei gambiense variant surface glycoproteins.Prevalence of human African trypanosomiasis in the Democratic Republic of the CongoDiagnostic accuracy of molecular amplification tests for human African trypanosomiasis--systematic review.Treatment of human African trypanosomiasis--present situation and needs for research and development.Identification of mimotopes with diagnostic potential for Trypanosoma brucei gambiense variant surface glycoproteins using human antibody fractions.Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal.Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness.Stage determination and follow-up in sleeping sickness.Trypanosomosis in goats: current status.Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness.Establishment of a panel of reference Trypanosoma evansi and Trypanosoma equiperdum strains for drug screening.Molecular analysis of archived blood slides reveals an atypical human Trypanosoma infection.
P50
Q24557540-5AE3B3FE-B0DD-42CB-9021-294E72D08B17Q24652225-B99D790B-72E0-43F3-9149-4BEF25704747Q28281992-B294115D-F89F-4985-95CE-587A7A614E25Q28475768-C09F9CC3-4C0D-4A1A-88E1-955B7D77B5A7Q28477800-29784A40-639B-451D-90BD-076CFEB62C4DQ28534313-BCD15686-E52F-46DE-90EC-16CF6EDF98F3Q28542468-1F192E80-5833-448F-B4DB-CB081EB64D1EQ28543489-6C1054F5-67C0-4ED7-8C2D-72D5D99578D5Q28551143-0A27C01F-473D-4FEE-87A5-DD156492446DQ28551452-CC86AA76-CF61-43C5-BBD9-CACE37B9A3EAQ30476076-A6917025-83A1-404F-9C2D-B0A07228B90BQ30755619-A7044EF6-DF93-448C-9359-524F54CCE6F3Q30863733-D7BBCE5A-64A6-4D4B-9299-BE53B52A9A26Q30914428-A14975D8-E62D-4B29-A5CC-7E6EDA8D80ADQ30938677-24C8FBA7-5DDC-4BA9-A052-3DC6FD704FDFQ33463411-3D47CD2A-64D6-42A0-8E77-8A26CDA24F67Q33528943-5066BC9C-91E0-4B5F-A7F9-38BEF822E2D8Q33584456-8C7FDE3C-0C10-43AD-9A28-17348150E308Q33631307-3DD133E6-5963-4AAD-B178-BF8B64BDB788Q33651126-51BDA594-87DA-44D1-A568-AB6ECCE500AEQ33748367-6BEBF28B-8DE4-4FA3-A8A2-DB466AC07546Q33776699-B727EC2D-63B1-485D-9916-5F2E5B7F4314Q33784142-A6C1EE3B-8410-46B2-954B-57E758464023Q33802931-E06B0A1D-DD24-435F-9A89-90828F772B42Q33833590-9BD57180-6EE1-4D10-B85C-77401DFC20E7Q33834052-67FCF6E3-4CF7-4DCB-9F3B-53CCFEC0D79BQ33880764-88430ACF-AD89-4F82-9861-7715FBB9B1D1Q33916128-590FBFC1-74F5-46FA-90C0-A88DDC9196D4Q33939308-896283A5-261C-43AC-9ACE-0BDEE184DA62Q33988882-81494433-6DCE-45DA-82B5-AB7068E43738Q34131218-2DCF72C3-972F-4BD2-9D88-BF1235717C27Q34139907-A89392DB-710E-44FF-8056-70F5E06A9AD1Q34312405-53C6F372-F53E-4626-B2E6-9AB340537261Q34312428-F0DB2920-D4F5-44CD-9CB5-3CC10737246BQ34345396-3F98F7ED-CAFA-40A0-A9D8-7F2F48D29EE8Q34502301-9FCE4DC1-67A7-494E-A061-90632E780D0DQ34572896-F08BC501-4B68-4063-82D7-134AD3EF25C4Q34613654-AC822C36-D6A8-4A2A-A828-E868F073BFACQ34648879-C0E6B5E3-7382-4ACD-8105-1DA0B43EA026Q34775781-0CDA06DC-D1BE-4066-B40A-44DFD3F99730
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-1926-7472
@en
name
Philippe Büscher
@ast
Philippe Büscher
@en
Philippe Büscher
@es
Philippe Büscher
@nl
type
label
Philippe Büscher
@ast
Philippe Büscher
@en
Philippe Büscher
@es
Philippe Büscher
@nl
altLabel
Buscher P
@en
Buscher P.
@en
Buscher
@en
Büscher P
@en
Büscher P.
@en
Büscher
@en
P Buscher
@en
P Büscher
@en
P. Buscher
@en
P. Büscher
@en
prefLabel
Philippe Büscher
@ast
Philippe Büscher
@en
Philippe Büscher
@es
Philippe Büscher
@nl
P1053
B-9956-2012
P106
P1153
55943912400
P21
P31
P3829
P3835
philippe-bscher
P496
0000-0002-1926-7472